Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings

New evidence

We found 1 new study in a search for systematic reviews published between 12 December 2014 and 18 July 2016. We also considered 7 additional studies identified by members of the guideline committee who originally worked on this guideline.

Evidence identified in previous surveillance 2 years and 4 years after publication of the guideline was also considered. This included 5 studies identified by the Evidence Update and 47 studies identified by the 4-year surveillance review.

From all sources, 60 studies were considered to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: summary of new evidence from surveillance and references for all new evidence considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.

Views of stakeholders

Stakeholders are consulted only if we decide not to update the guideline following checks at 4 and 8 years after publication. Because this was a 6-year surveillance review, and the decision was not to update, we did not consult on the decision.

See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett
Associate Director

Philip Alderson
Consultant Clinical Adviser

Katrina Sparrow
Technical Adviser

Omar Moreea
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2206-2